Skip to content
OpenCapital
Get started

Adaptive Biotechnologies ADPT Immune Medicine Business — Adjusted Ebitda

Similar metrics at other companies

Cleveland-Cliffs logo
CLFOther Businesses — Adjusted EBITDA
$15M+50.0%
AVT
AVTRBioscience & Medtech Products — Adjusted Operating Income
$102.7M-10.3%
International Flavors & Fragrances logo
IFFHealth & Biosciences — Adjusted Operating EBITDA
$153M+10.9%
IDEX logo
IEXHealth & Science Technologies — Segment Adjusted EBITDA
$106M+21.3%
Medline, Inc. logo
MDLNMedline Brand — Segment adjusted EBITDA
$765M-7.8%
Jones Lang LaSalle logo
JLLInvestment Management — Adjusted EBITDA
$15M-5.1%

Other financials

Income statement

See full
Revenue$70.9M+35.1%
Gross profit$52.2M+47.1%
Operating income-$19.2M+35.1%
Net income-$20.0M+32.9%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$77.6M+53.2%
Total debt$208.2M-5.6%
Total equity$216.3M+13.6%
Total assets$505.9M-1.0%

Cash flow

See full
Operating cash flow-$9.5M+66.5%
CapEx$796.0K-36.8%
Free cash flow-$10.3M+65.3%

Valuation

See full
Market cap$2.76B+93.6%
Enterprise value$2.89B+78.0%
P/S9.3×+1.8×

Profitability

See full
Gross margin75.3%+12.7pp
Operating margin-15.8%-7.0pp
Net margin-16.8%-7.3pp
FCF margin-10.5%-4.6pp

Returns & leverage

See full
Return on equity-24.4%-9.2pp
Debt / equity1×-0.2×
Current ratio3.4×+0.4×

Where this comes from

Reported directly by Adaptive Biotechnologies in its filing.

Tagged under the XBRL concept adpt:AdjustedEbitda.

The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Adaptive Biotechnologies's immune medicine business — adjusted ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Adaptive Biotechnologies's immune medicine business — adjusted ebitda?
Adaptive Biotechnologies (ADPT) reported immune medicine business — adjusted ebitda of -$10.36M in Q1 2026.
How has Adaptive Biotechnologies's immune medicine business — adjusted ebitda changed year-over-year?
Adaptive Biotechnologies's immune medicine business — adjusted ebitda decreased by 102.9% year-over-year, from -$5.11M to -$10.36M.
What is the long-term trend for Adaptive Biotechnologies's immune medicine business — adjusted ebitda?
Over 2 years (2022 to 2024), Adaptive Biotechnologies's immune medicine business — adjusted ebitda has grown at a -26.9% compound annual growth rate (CAGR), from -$45.65M to -$24.41M.
What does immune medicine business — adjusted ebitda mean?
This metric measures the operational profitability of the Immune Medicine Business segment by excluding interest, taxes, depreciation, amortization, and other non-cash or non-recurring items. It provides a normalized view of the segment's core earnings power and operational efficiency.